Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Net Income (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Net Income for 8 consecutive years, with -$29.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income rose 18.75% year-over-year to -$29.8 million, compared with a TTM value of -$95.1 million through Sep 2025, down 467.43%, and an annual FY2024 reading of -$37.4 million, up 62.98% over the prior year.
  • Net Income was -$29.8 million for Q3 2025 at X4 Pharmaceuticals, down from -$25.7 million in the prior quarter.
  • Across five years, Net Income topped out at $90.8 million in Q2 2024 and bottomed at -$55.7 million in Q2 2023.
  • Average Net Income over 5 years is -$19.8 million, with a median of -$22.0 million recorded in 2022.
  • Peak annual rise in Net Income hit 263.04% in 2024, while the deepest fall reached 1492.02% in 2024.
  • Year by year, Net Income stood at -$30.2 million in 2021, then increased by 3.65% to -$29.1 million in 2022, then skyrocketed by 34.27% to -$19.1 million in 2023, then crashed by 108.16% to -$39.8 million in 2024, then grew by 25.13% to -$29.8 million in 2025.
  • Business Quant data shows Net Income for XFOR at -$29.8 million in Q3 2025, -$25.7 million in Q2 2025, and $282000.0 in Q1 2025.